Search hospitals

>

Minnesota

>

Saint Paul

United Hospital

Claim this profile

Saint Paul, Minnesota 55102

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Pancreatic Cancer

548 reported clinical trials

16 medical researchers

Photo of United Hospital in Saint PaulPhoto of United Hospital in Saint PaulPhoto of United Hospital in Saint Paul

Summary

United Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. United Hospital is involved with conducting 548 clinical trials across 544 conditions. There are 16 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.

Area of expertise

1

Breast Cancer

Global Leader

United Hospital has run 106 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
Stage IV
ER positive
2

Lung Cancer

Global Leader

United Hospital has run 81 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at United Hospital

Lung Cancer

Breast Cancer

Esophageal cancer

Prostate Cancer

Breast cancer

Non-Small Cell Lung Cancer

Colorectal Cancer

Cancer

Ovarian Cancer

Multiple Myeloma

Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Stereotactic Radiosurgery vs Whole-Brain Radiotherapy

for Brain Metastasis from Lung Cancer

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at United Hospital?

Where is United Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does United Hospital accept?

What awards or recognition has United Hospital received?